Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER negative, HER2-negative, PR negative status confers therapeutic sensitivity to Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin (AUC 6) and weekly packlitaxel (80 mg/m^2) followed by dose dense doxorubicin cyclophosphamide for reimbursement as a treatment option for the neoadjuvant treatment of triple negative breast carcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
Neoadjuvant treatment of triple negative breast carcinoma.